Loading provider…
Loading provider…
Hematology & Oncology Physician in Fort Worth, TX
NPI: 1962452474Primary Practice Location
TEXAS HEALTH HARRIS METHODIST HOSPITAL FORT WORTH
1301 Pennsylvania Ave, Fort Worth, TX
Primary Employer
The Center for Cancer and Blood Disorders - Las Colinas
thecentertx.com
HQ Phone
Get Dr. Robyn's Phone Numberphone_androidMobile
Get Dr. Robyn's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
1991 - 2025
TX State Medical License

American Board of Internal Medicine
Medical Oncology
SUNY Upstate Medical University
upstate.edu
Fellowship • Hematology and Medical Oncology
1993 - 1995
Residency • Internal Medicine
1990 - 1993
McGovern Medical School
med.uth.edu
Medical School
Until 1990
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | J0897Injection, denosumab, 1 mg | 23 | 4,020 |
| 2 | J1100Injection, dexamethasone sodium phosphate, 1 mg | 16 | 980 |
| 3 | J2469Injection, palonosetron hcl, 25 mcg | 13 | 830 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 314 | 536 |
| 5 | J3489Injection, zoledronic acid, 1 mg | 71 | 424 |
Authors: Lowell Hart, Gail Wright, Amy Chien, Ian Krop, Vandana Abramson, Hope Rugo
Journal: Breast Cancer Res Treat
Publication Date: 2021-02-16
Authors: Adam Brufsky, Joyce O'Shaughnessy, Haythem Ali
Journal: Ann Oncol
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Authors: Mikhail Shtivelband, Huilin Li, Sharon Wilks, Stefan Gluck, Joyce O'Shaughnessy, Haythem Ali
Publication Date: 2018-06-08
Lead Sponsor: Boehringer Ingelheim
Intervention / Treatment: DRUG: Placebo, DRUG: Exemestane, DRUG: Everolimus, DRUG: Xentuzumab
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Ribociclib, DRUG: Adjuvant endocrine therapy
Lead Sponsor: Agendia
Intervention / Treatment: DIAGNOSTIC_TEST: MammaPrint, BluePrint, and Full-Genome Testing